Authors: Rudin, CM Holmlund, J Fleming, GF Mani, S Stadler, WM Schumm, P Monia, BP Johnston, JF Geary, R Yu, RZ Kwoh, TJ Dorr, FA Ratain, MJ

Citation: Cm. Rudin et al., Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer, CLIN CANC R, 7(5), 2001, pp. 1214-1220

Authors: Stepkowski, SM Chen, W Geary, R Yang, ME Condon, T Stecker, K Bennett, CF

Citation: Sm. Stepkowski et al., Development of an oral formulation for ICAM-1 antisense oligonucleotides, TRANSPLAN P, 33(1-2), 2001, pp. 387-387

Authors: Leeds, JM Henry, SP Geary, R Burckin, T Levin, AA

Citation: Jm. Leeds et al., Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys, ANTISENSE N, 10(6), 2000, pp. 435-441

Authors: Nemunaitis, J Holmlund, JT Kraynak, M Richards, D Bruce, J Ognoskie, N Kwoh, TJ Geary, R Dorr, A Von Hoff, D Eckhard, SG

Citation: J. Nemunaitis et al., Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer, J CL ONCOL, 17(11), 1999, pp. 3586-3595

Authors: Monteith, DK Horner, MJ Gillett, NA Butler, M Geary, R Burckin, T Ushiro-Watanabe, T Levin, AA

Citation: Dk. Monteith et al., Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys, TOX PATHOL, 27(3), 1999, pp. 307-317